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Abstract
Nasopharyngeal carcinoma is an uncommon cancer in North America. Its clinical course is typified
by locally advanced disease at diagnosis and has a high propensity for both regional and distant
spread. It is, therefore, typically treated with a combination of radiation and chemotherapy. This
report describes our 10-year clinical and radiological findings in a 48-year-old Vietnamese male
patient with locally-advanced T4N1M0 lympho-epithelial carcinoma of the nasopharynx. Despite a
long remission period after his initial course of aggressive chemoradiation, his tumor recurred
locally after 4 years. Thereafter, throughout a period of over 10 years, he has been treated with
multiple courses of re-irradiation and three different trials of chemotherapy. He was ultimately
provided with over 30 months of progression-free tumor control with the epidermal growth factor
receptor (EGFR)-inhibitor cetuximab. This case illustrates the commonly protracted course of this
disease and its responsiveness to multiple treatment modalities.
Introduction
Nasopharyngeal carcinoma (NPC) is a squamous cell car-
cinoma that occurs in the epithelial lining of the
nasopharynx. In the United States and Western Europe,
nasopharyngeal carcinoma is a relatively rare. It is more
common among Southern Chinese, Southeast Asian,
Northern African, and Eskimo populations [1]. Among
head and neck cancers, NPC has the highest propensity
for developing distant metastases. Histologies of NPC
range from well-differentiated squamous carcinoma
(WHO type I), to non-keratinizing squamous carcinoma
(WHO type II), to lympho-epithelial carcinoma (WHO
type III), where non-keratinizing squamous carcinoma
cells are mixed with numerous benign lymphocytes. Type
III cancers are regarded as having the highest response to
treatment, but also the greatest propensity for developing
distant micrometastatic spread. Due to the anatomical
location of the disease, NPC is typically not treated with
surgical resection; rather concurrent chemoradiotherapy
is the preferred approach. Cisplatin with radiation fol-
lowed by adjuvant chemotherapy has been reported to be
more effective in patients with NPC than with radiation
alone [2,3], and this approach has now been adopted as
current standard of care. Despite this combined approach,
31% of patients will develop recurrent disease[2].
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oclonal antibody, binds specifically to the epidermal
growth factor receptor (EGFR, HER1, c-ErbB-1) and com-
petitively inhibits the binding of epidermal growth factor
(EGF). This results in inhibition of cell growth, induction
of apoptosis, and decreased matrix metalloproteinase and
vascular endothelial growth factor production [4]. This
drug has proven clinical benefit as a single agent in
patients with recurrent or metastatic squamous cell carci-
noma of head and neck [5,6]. Additionally, a phase III
trial was published showing improved local control and
overall survival in patients treated with cetuximab plus
radiation compared to radiation alone [7].
The following case report describes a Vietnamese male
with a 10-year clinical course of lympho-epithelial carci-
noma of the nasopharynx who failed multiple therapies
involving both chemotherapy and radiation, but was able
to achieve stable disease for over 30 months with EGFR
inhibition.
Case report
In October 1997, a 39 year old immigrant from Vietnam
presented with right-sided headache, otalgia, and tinnitus
over the previous month. He was discharged with clari-
thromycin for suspected otitis media. One month later, he
returned with severe right otalgia which now radiated to
the vertex of his skull. He re-presented with continued
symptoms. Endoscopic exam revealed a large mass ema-
nating from the nasopharynx. Biopsy was performed, with
surgical pathology revealing poorly-differentiated inva-
sive lympho-epithelial nasopharyngeal carcinoma (Figure
1). Stains for the Epstein Barr Virus (EBV) latent mem-
brane protein were negative in the neoplastic cells (Figure
2). This test, however, is not as sensitive or specific as the
EBER test which was not available at the time. Neck MRI
confirmed a large 4.0 × 4.7 × 5.4 cm mass emanating from
the nasopharynx and invading the orifice of the right Eus-
tachian tube. A necrotic cervical lymph node in the right
spinal accessory chain was pathologically enlarged at 1.3
cm and was suspicious for metastatic disease (Figure 3,
part A). Chest x-ray and bone scan were negative, and liver
function tests were within normal limits. He was staged
(AJCC staging 1997) with stage T4N1M0 nasopharyngeal
carcinoma.
The patient was referred for chemoradiation treatment,
and in 11/1997, he began concurrent cisplatin (100 mg/
m2) with concomitant 3D conformal radiation therapy
consisting of 66 Gy in 33 fractions of 2.0 Gy. During radi-
otherapy, he developed severe mucositis, dysphagia and
odynophagia requiring temporary PEG tube placement.
Post-treatment MRI in 1/1998 showed marked interval
decrease in size of the right nasopharyngeal tumor, which
now measured approximately 2.2 × 1.3 cm. Repeat MRI in
2/1998 showed a small quantity of residual fullness in the
right nasopharynx (Figure 3, part B). The patient, there-
fore, subsequently received a stereotactic radiosurgical
boost (1200 cGy in one fraction) to the residual abnor-
mality as well as three cycles of adjuvant 75 mg/m2 cispl-
atin and 5-fluorouracil 1 g/m2 (d1-5) every 21 days. The
patient did not tolerate this regimen well with the devel-
opment of leukocytopenia and grade IV mucositis, which
Pathology from original biopsyFigure 1
Pathology from original biopsy. Note the characteristic 
proliferation of cells arranged in a syncytial pattern as well as 
the vesicular nuclei with prominent nucleoli and areas of 
keratinization.
Negative EBV latent membrane staining of biopsy specimenFigure 2
Negative EBV latent membrane staining of biopsy 
specimen. This test, however, is not as sensitive or specific 
as the EBER test which became available after this patient 
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Multiple MRI scans of the nasopharynx listed in chronological order showing the progression of disease after multiple treat-mentsFigure 3
Multiple MRI scans of the nasopharynx listed in chronological order showing the progression of disease after 
multiple treatments. In Part A and B, the extent of the tumor was indicated with the white enclosed areas. In Part C to H, 
boundaries of the tumor are indicated (arrows). Dosimetries of the radiosurgery are indicated in Part B and D (concentric 
curved circles). Part F contained FDG-PET scan of the same period in the same nasopharyngeal plane as the MRI.
Head & Neck Oncology 2009, 1:18 http://www.headandneckoncology.org/content/1/1/18necessitated a 50% reduction of cisplatin and 5-FU dose
on cycles 2 and 3.
By 6/1998, however, the patient had recovered well and
showed no evidence of disease on physical and endo-
scopic examination. MRI 7/1998 showed no obvious dis-
ease, only slight soft tissue asymmetry within the
nasopharynx. He remained disease-free on frequent fol-
low-up examinations and MRI until 5/1999, when he pre-
sented with severe, crippling, lancinating headaches that
initiated at the occiput and radiated to his right eye. This
was associated with severe fatigue, weakness, and gait
instability. An MRI at that time showed no evidence of
disease (Figure 3, part C). Therefore, the patient was
treated conservatively with Gabapentin for presumed neu-
ropathic pain that provided good symptomatic relief. He
remained clinically NED for over 2 years.
However, in 11/2001, almost 4 years after the treatment
of his initial disease, repeat neck CT showed an interval
increase in the asymmetry seen within the soft tissue of his
right nasopharynx. Flexible fiberoptic endoscopy revealed
a right-sided 1 cm nasopharyngeal ulcer in the fossa of
Rosenmüller. The patient was scheduled for a biopsy of
the lesion, but the patient missed the subsequent appoint-
ment. In 1/2002, he did return to the clinic but reported
symptoms of dizziness, fullness of his ears, fatigue, and
occasional headache. He was unable to tolerate solid
food. Repeat MRI showed persistent fullness within the
right fossa of Rosenmüller. However, the size of the soft
tissue abnormality remained unchanged compared with
the prior CT. On 1/29/2002, nasal endoscopy with
nasopharyngeal biopsy revealed poorly-differentiated
nasopharyngeal carcinoma identical to his initial tumor
histology (Figure 4). Both MRI and CT in 3/2002 were
used to outline the area of recurrence (Figure 3, part D)
and he subsequently underwent LINAC-based stereotactic
radiosurgery as salvage treatment, delivering 2000 cGy in
a single fraction to the periphery of the tumor. The treat-
ment was well tolerated with no major complications.
Repeat MRI in 5/2002 showed a significant decrease in the
right-sided nasopharyngeal fullness, but some right para-
pharyngeal edema remained (Figure 3, part E). The
patient noted no significant detriment in his swallowing
or speech. Almost one year later, in 4/2003, he reported
numbness over the right trigeminal (V1-V3) dermatomes
as well as right ear hearing loss and epistaxis. Unfortu-
nately, the patient missed several of his follow-up and
MRI appointments.
When he returned to clinic in 9/2004, his MRI showed sig-
nificant progression of disease. There was a 3 cm mass that
extended through the right skull base and foramen ovale.
Additionally, tumor was seen in the right pterygopalatine
fossa with destruction of the posterior maxillary sinus
extending to the posterior aspect of the right orbit. The
tumor also extended laterally to the infratemporal fossa,
invading the medial and lateral pterygoid muscles. There
was tumor invasion into the longus coli muscle and the
perivertebral space with involvement of the jugular tuber-
cle and right jugular foramen. The mass extended inferi-
orly to the right tonsils, and there were multiple
pathologically-enlarged right submandibular and sub-
mental lymph nodes (Figure 3, part F).
The patient subsequently received weekly chemotherapy
with carboplatin and paclitaxel in 9/2004 for palliation of
symptoms. During treatment, patient reported trismus
and right ear/jaw pain, and he was started on amoxicillin
for a possible infectious process. Repeat MRI of 12/2004
showed slight interval decrease in the size of the skull base
component of the nasopharyngeal mass when compared
to the 9/2004 study. However, the tumor showed evi-
dence of perineural spread and direct invasion into the
skull base and right cavernous sinus as well as into the
pterygopalatine fossa and right muscles of mastication.
He continued on weekly carboplatin/paclitaxel. Repeat
MRI 2/2005 showed minimal decrease in the size of the
nasopharyngeal portion of the mass. Moreover, the
patient became leukopenic which prompted cessation of
treatment. With limited options by 3/2005, the patient
underwent re-irradiation in the form of intensity-modu-
lated radiation therapy (IMRT) given 120 cGy BID for a
total of 60 Gy over 5 weeks to gross sites of disease. Treat-
ment significantly overlapped previously irradiated sites
from both his initial 3D radiation and radiosurgery treat-
ment. When his white blood count returned to normal on
Pathology from recurrence in 1/2002Figure 4
Pathology from recurrence in 1/2002. Note the 
increased tumor necrosis compared to 1997.Page 4 of 8
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and paclitaxel was initiated. Concurrent chemoradiation
was completed by 4/13/05. The patient had developed
dysphagia, trismus, persistent xerostomia, grade 3
mucositis, excessive mucus production, and fatigue. Post-
treatment MRI 06/05 showed an overall reduction in bulk
of the right nasopharyngeal mass and stable appearance
of tumor extension into the right cavernous sinus, ptery-
opalatine fossa, and skull base.
In 08/2005, patient was admitted to inpatient oncology
service for 7 days for nausea/emesis along with trismus,
decreased oral intake, and resultant dehydration. Exten-
sive scarring of the TMJ from prior tumor and radiation
therapy was apparent on exam. To avoid airway compro-
mise and improve nutrition, tracheostomy was per-
formed, and an open gastrostomy tube was placed.
During the hospital admission, MRI showed marked pro-
gression of disease. A large necrotic mass centered in the
right nasopharyngeal region, extending inferiorly to the
level of the right pyriform sinus as well as anteriorly into
the infratemporal fossa, was seen. There was again evi-
dence for intracranial extension of disease (Figure 3, part
G). Hospice care was recommended to the patient and his
family, but the patient declined.
The patient therefore went on to receive cetuximab from
10/2005 to 3/2006, at 400 mg/m2 loading dose and
weekly doses of 250 mg/m2. After 3 treatments, he
reported a marked decrease in pain and significant
improvement in the range of motion in his neck. Repeat
MRI 4/2006 revealed no significant disease progression
(Figure 3, part H). By this time, the patient had returned
to a normal activity level and had pain level ranging 0–2/
10 without medication. Repeat MRI 1/07 remained stable.
Unfortunately, in 2/2007, patient was noted to have a
new right-sided facial droop along with a new anaerobic
smell and facial pain. He was again reinitiated on weekly
cetuximab therapy, at a loading dose of 400 mg/m2 fol-
lowed by weekly maintenance of 250 mg/m2. After his
first cycle, he noted improved breathing through his right
nostril and decreased odor. By his third cycle, he had
developed a grade 2 acneiform rash over his face, scalp,
and trunk, which was treated with doxycycline 100 mg
BID. He was maintained on cetuximab through 8/2007,
when MRI in 8/2007 continued to reveal stable disease.
Throughout his 6-month course of cetuximab, he devel-
oped significant issues with hypokalemia attributed to
cetuximab. This resolved after treatment was discontin-
ued.
The patient remained stable off any systemic therapy until
7/2008. At that time, he developed clinical local progres-
sion of disease resulting in epistaxis, increased odor, and
breakdown tissue in preauricular region. MRI revealed
increasing abnormal enhancement and mass involving
the right nasopharyngeal cavity extending into the right
cavernous sinus, middle cranial fossa, and dural surface.
He was subsequently given 40 mg/m2 methotrexate and
clindamycin. There appeared to be an initial clinical
response, with decreased erythema in the preauricular
region, increased energy, and less odor. However, in 10/
2008, progression of disease was demonstrated by
increased sinus congestion, bleeding, and odor despite
aggressive oral hygiene and antibiotic treatment. Addi-
tionally, MRI revealed tumor progression into the nasal
cavity.
The patient was being considered for a phase I trial, but
his tumor was rapidly progressing with worsening of his
symptoms. He therefore was placed on weekly 450 mg/m2
5-fluorouracil (5-FU) and 20 mg/m2 leucovorin in 11/
2008. Surprisingly, his symptoms have improved signifi-
cantly. During treatment through 1/21/2009, he devel-
oped neutropenic fever which required hospitalization
and IV antibiotics. Presently, the patient is scheduled to
resume his systemic therapy.
A summary of the patient's disease and treatment course
can be found in table 1.
Discussion
In this case report, we present a patient with locoregion-
ally advanced lympho-epithelial carcinoma of the
nasopharynx. Nasopharyngeal carcinoma typically origi-
nates in the fossa of Rosenmüller. Since this is a clinically
occult site, patients often remain asymptomatic for a rela-
tively prolonged period. Frequently, symptoms of
epistaxis, nasal congestion, or otitis media are treated for
benign etiologies which defer a definitive diagnosis
(mean 7.2 months in one series) [8]. Consequently, more
than 90 percent of patients present with locally and/or
regionally advanced disease at diagnosis, often with cra-
nial nerve defecits and/or massive cervical adenopathy
[9,10]. Additionally, a high incidence (20–40%) of dis-
tant metastases has been reported [11].
Due to anatomical limitation to surgical interventions,
radiotherapy with chemotherapy is the preferred choice of
treatment. The most pivotal trial investigating the use of
chemoradiation in the treatment of nasopharyngeal can-
cer came from the Intergroup. The chemotherapy regimen
consisted of cisplatin during radiation and cisplatin and
5-FU adjuvant. The 3 year progression free survival was
69% in the chemoradiation arm versus 24% with radia-
tion alone. Overall survival at 3 years was 76% with chem-
oradiation versus 46% for radiation alone. Not
surprisingly, there was a higher incidence of grade 3–4Page 5 of 8
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otherapy[2]. Multiple subsequent trials have yielded sim-
ilar results [12-17]. These findings have substantiated
chemoradiation for nasopharyngeal cancer. Additionally,
the 5-year overall survival was 37% for WHO I, 55% for
WHO II, and 60% for WHO III [18].
However, nasopharyngeal carcinoma still has a recurrence
rate of 31% post-chemoradiation therapy at 3 years [2].
External beam radiation, in the form of intensity-modu-
lated radiation, stereotactic radiosurgery, hyperfraction-
ated radiation, or intracavitary brachytherapy may be
options for patients who have a local or regional recur-
rence. Induction chemotherapy with agents such as cispl-
atin, taxanes, 5-fluoruracil, or gemcitabine may be
considered prior to re-irradiation [19].
Stereotactic radiosurgery (SRS) uses three dimensional
planning and techniques to precisely deliver narrowly col-
limated beams of ionizing radiation in a single high-dose
fraction to small (<4 cm) targets. Administering an SRS
boost following external beam RT may improve local con-
trol in locally advanced NPC. In one series, all of 23 con-
secutive patients with stage IV disease receiving an SRS
boost following fractionated RT were locally controlled at
a mean follow-up of 21 months, although eight subse-
quently developed regional or distant metastases [20].
Stereotactic techniques and proton beam therapy have
also been used to salvage patients with locally recurrent or
persistent disease. As an example, in a report of 36
patients with recurrent NPC who were re-irradiated with a
radiosurgical boost, the three year locoregional control
rate was 56 percent, and a five-year survival of 49 percent
[21,22].
Cetuximab, a monoclonal chimeric antibody, inhibits
EGFR, which is over-expressed in the vast majority of head
and neck cancers [23]. Cetuximab inhibits receptor activ-
ity by blocking the ligand binding site. In addition to its
potential as a radiation sensitizer [7,24], cetuximab has
also been investigated as a single agent, and in combina-
tion with cytotoxic agents in patients with advanced head
and neck cancer [25-28]. The benefit of cetuximab as a
radiation sensitizer was tested in a multinational trial in
which 424 patients with locoregionally advanced SCC of
the oropharynx, hypopharynx, or larynx were randomly
assigned to radiotherapy (once daily, twice daily, or with
a concomitant boost, with the specific approach selected
by each participating institution) with or without weekly
concurrent cetuximab [7]. With a median follow-up of 54
months, the cetuximab-treated group had significantly
better median (49 versus 29 months) and three-year sur-
vival (55 versus 45 percent) compared to those receiving
radiation alone. Locoregional control rates were also sig-
nificantly better (50 versus 41 percent), and in a separate
report, there was also a suggestion of a higher laryngeal
preservation rate in the cetuximab group (88 versus 80
percent at three years, respectively) [24]. The cumulative
rate of distant metastases at two years was similar (16 ver-
sus 17 percent, respectively) [7].
Cetuximab has also been shown to increase locoregional
disease control as well as stabilizing distant metastasis
when given alone [4]. In the case of our patient, after
Table 1: Summary and outcomes of total radiation and chemotherapy received.
Date Time to progression Radiation target Type of radiation therapy Other therapy
11/97 – 01/98 N/A Nasopharynx 3D Conformal, 66 Gy/2.0 Gy in 33 
fractions
Concurrent Cisplatin + 5 FU
02/98 4 years Nasopharynx Stereotactic radiosurgery, 12 Gy in 1 
fraction
Adjuvant Cisplatin + 5 FU
03/02 2 years Nasopharynx Stereotactic radiosurgery, 12 Gy in 1 
fraction
None
09/04 – 02/05, 03/05 – 04/05 12 months Nasopharynx IMRT, 60 Gy/1.2 Gy in 50 fractions Concurrent Carboplatin + Taxol
10/05 – 03/06, 02/07 – 08/07 30 months N/A N/A Cetuximab
07/08 – 10/08 0 months N/A N/A Methotrexate
11/08 – present TBD N/A N/A 5 FU + leucovorin
Total Radiation Received: 158 Gy to the nasopharynxPage 6 of 8
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therapy was no longer deemed a viable option. Since the
patient had failed multiple chemotherapy regimens
including cisplatin, 5-FU, carboplatin, and paclitaxel,
cetuximab was considered a reasonable choice in this
patient. Anecdotally, it provided over 30 months of pro-
gression-free tumor control. Toxicities from this therapy
included acneiform rash and hypokalemia.
In summary, lympho-epithelial carcinoma of the
nasopharynx often exhibits a protracted course and
responds to multiple treatment modalities. Up-front
standard of care therapy includes concurrent cisplatin and
radiation followed by adjuvant cisplatin and 5-FU. More
commonly, induction chemotherapy is used for better tol-
erance. Despite excellent 5 year survival data with this
treatment approach, a substantial proportion of patients
recur, as illustrated by our patient. After exhausting multi-
ple therapeutic strategies, EGFR inhibition afforded him
over 30 months of progression-free tumor control and sig-
nificant palliation.
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